Unlock the potential of your antibody-drug conjugate development by partnering with our experts in bioconjugation to ensure the efficacy, safety, and scalability of your innovative therapies.
Leveraging robust analytical services at every stage of development and manufacturing is crucial to ensure your therapy reaches patients in need on time and within budget.
Partner with a global network of cGMP-certified mammalian cell culture manufacturing facilities to ensure scalable, high-quality biologics production and seamless global supply.
Aragen offers a choice of cell line development platforms and coefficient upstream and downstream process development. We use nonproprietary, commercially available media and feed.
We’ve helped develop and commercialize particle engineering based drug delivery platforms and supported development and commercialization of enhanced drug products.
Discover how advanced mRNA manufacturing innovations, including optimized RNA synthesis and scalable LNP encapsulation, are accelerating therapeutic development.
Catalent’s GPEx® Lightning cell line development technology, a standardized, scalable platform, addresses production challenges associated with expression and scalability of complex biologics.
From early-stage development and clinical trials to full-scale commercial production, our mission is to bring hope to life by enabling life-changing therapies for patients around the world.
Curia offers comprehensive development and manufacturing services to meet needs through the entire lifecycle of your sterile drug product. Leverage our in-depth expertise and capabilities.
Learn how this transient platform accelerates biologics production, seamlessly transitioning from discovery to stable CHO-K1, ensuring scalability, and reducing risks in manufacturing biologics.
